Compare Visa Inc (V) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Visa Inc trades at $369.32 (market cap $693.57B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Visa Inc is far larger — about 5.2× Vertex Pharmaceuticals Incorporated's market cap, and Visa Inc pays a 0.73% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| V | VRTX | |
|---|---|---|
Market Cap | $693.57B | $134.06B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $384.14 | $557.96 |
52-Week Low | $295.52 | $376.62 |
Enterprise Value | $704.15B | $128.18B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $368.64, down 1.71% on the day, amid a bullish technical setup with strong support at $366 and resistance at $372. The company reported robust fundamentals with Q2 2026 earnings beating estimates, revenue growth to $40B in 2025, and a net income margin of 50.78%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, signaling innovation in payments.
Outlook remains positive with an analyst consensus price target of $430.93 (17% upside), supported by high profitability and strategic initiatives. Risks include fintech competition and regulatory pressures, but institutional ownership trends and a debt-to-asset ratio of 25.26% reflect financial stability. The stock presents a long-term growth opportunity with manageable headwinds.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
